Michigan State's Jamie Alan calls the move dangerous, while the Alliance for Pharmacy Compounding says licensed pharmacies beat gray-market vials.
Recap by typeshit. Full story at Yahoo.
A shared explainer on how eating habits and food choices matter once you begin a GLP-1 medication. General guidance, no new findings.
Williams explains how retatrutide's glucagon pathway works and cautions that knockoff Reta sold online is a real risk. FDA approval could come in late 2027 or 2028.
A brief post argues buyers need accurate information on peptides because a lot of the popular messaging is misleading.
Men's Journal reports the coroner's findings on the cause of Norton's death, with the dose detail coming from the coroner rather than earlier speculation.
The posters cover baseline traits in the phase 3 VANQUISH-2 trial and cardiometabolic measures from the phase 2 VENTURE study, November 14 to 17.
Healio
At a Boston masterclass, the Harvard obesity doctor said GLP-1s should be treated as indefinite care, since weight returns when they stop.
Loading…